Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots
- First Online:
- Cite this article as:
- Dicker, A., Rydén, M., Näslund, E. et al. Diabetologia (2004) 47: 420. doi:10.1007/s00125-003-1324-0
Regional differences in lipolysis, with higher lipolytic activity in visceral than subcutaneous fat, are important for the development of insulin resistance and might be influenced by testosterone.
We studied testosterone-regulated lipolysis and protein expression (by western blot) in fully differentiated pre-adipocytes from visceral (omental) and abdominal subcutaneous adipose tissue from 52 human subjects. These cells were isolated and cultured in a serum-free medium.
Testosterone caused a specific, time- and concentration-dependent 50% reduction of catecholamine-stimulated lipolysis in the subcutaneous depot. Half of the maximum effect occurred at 10 nmol/l. The inhibitory effect was due to the inability of β-adrenoceptors and cyclic AMP to stimulate the protein kinase A, hormone-sensitive lipase complex. Testosterone caused a depot-specific 50% reduction of the protein expression of hormone-sensitive lipase and β2-adrenoceptors in differentiated subcutaneous pre-adipocytes, but no change in β1-adrenoceptors, protein kinase A subunits or perilipin expression. In contrast, testosterone had no effect on lipolysis or protein expression in the visceral depot. However, testosterone receptors were present in both depots, and the hormone inhibited adipocyte leptin secretion. Similar effects on lipolysis were observed with dihydrotestosterone.
Testosterone in physiological concentrations causes a depot-specific reduction of catecholamine-stimulated lipolysis in subcutaneous fat cells, probably due to reduced protein expression of β2-adrenoceptors and hormone-sensitive lipase. This could be an important pathogenic factor underlying regional differences in lipolysis and development of insulin resistance and hyperandrogenic polycystic ovary syndrome.
KeywordsAdipose tissuecyclic AMPhormone-sensitive lipaselipolysisperilipinprotein kinase Atestosterone
polycystic ovary syndrome
protein kinase A
dibutyryl cyclic AMP
Adipose tissue plays an important pathophysiological role in several conditions featuring insulin resistance, e.g. upper-body obesity, glucose intolerance, insulin resistance, Type 2 diabetes, metabolic syndrome, dyslipidaemia and polycystic ovary syndrome (PCOS) [1, 2, 3, 4, 5]. Regional variations in adipose tissue function seem to have an additional bearing on insulin resistance, and visceral fat accumulation has a stronger association with insulin resistance than subcutaneous fat accumulation [6, 7, 8, 9, 10]. This has in part been attributed to higher lipolytic activity in visceral than in subcutaneous adipose tissue [6, 7, 8, 9, 10]. Catecholamines are the major lipolytic hormones in humans and catecholamine-stimulated lipolysis is higher in visceral fat cells than in subcutaneous adipocytes [6, 7, 8, 9, 10]. Moreover, due to portal vein drainage, high lipolytic activity in visceral fat cells leads to increased “portal” fatty acids which in turn alter liver function [6, 7, 8, 9, 10]. It is possible that liver dysfunction at least in part causes the glucose intolerance, hyperinsulinaemia and dyslipidaemia often observed in conditions characterised by insulin resistance.
The mechanisms behind the higher rate of catecholamine-induced lipolysis seen in visceral fat cells than in subcutaneous adipocytes are unknown. These regional variations in lipolysis are much more apparent in obese men than in obese women [11, 12]. In PCOS, which is a hyperandrogenic state , catecholamine-induced lipolysis is decreased in subcutaneous fat cells, but increased in visceral adipocytes [13, 14]. Finally, upper-body obesity is more common among men than among women [6, 7, 8, 9, 10]. Thus sex differences in lipolysis and the findings for PCOS suggest that testosterone could be involved in the regional differences in lipolysis.
We have recently developed a human in vitro model for mechanistic studies of regional differences in adipocyte lipolysis . In this model pre-adipocytes from fibroblast-like cells from the stromal vascular compartment of subcutaneous abdominal and omental (visceral) adipose tissue are isolated and differentiated into fat cells under defined conditions in a serum-free environment. These cells maintain the lipolytic phenotype of adult mature fat cells i.e. a high catecholamine-induced rate of lipolysis in the omental region and a low rate in the subcutaneous region . We investigated the importance of testosterone for lipolytic regulation in abdominal subcutaneous and omental pre-adipocytes differentiated in the above way.
Subjects and methods
The study comprised 52 women and 8 men undergoing elective surgery because of obesity, abdominal hernia or gall stones. They were otherwise healthy. There was no selection on the basis of age or body weight. Body mass index varied between 28 and 72 kg/m2. Age varied between 21 and 63 years. None of the subjects was on continuous medication. All subjects were operated in the morning, having fasted overnight. Only saline was given intravenously until adipose tissue was removed at the beginning of surgery. Subcutaneous adipose tissue was removed from the surgical incision and omental adipose tissue (5–10 g) was removed by laparoscopic procedures. The tissue was immediately brought to the laboratory for further processing. The study was carried out in accordance with the Declaration of Helsinki as revised in 2000. The hospital’s ethics committee approved the study, which was explained in detail to each subject. All subjects gave informed consent.
Isolation and culture of adipocyte precursor cells
The isolation and differentiation of pre-adipocytes was done as described , with recent modifications . Tissue fragments were incubated for 1 h at 37°C with 0.5 g/l of collagenase (Sigma, St. Louis, Mo., USA) in Krebs Ringer Phosphate buffer (pH 7.4) containing 40 g/l of dialysed BSA (fraction V, Sigma). The desegregated adipose tissue was filtered through a nylon mesh with a pore size of 250 µm and the cell suspension was centrifuged for 10 min at 200 g at room temperature. The pellet was resuspended and incubated in 10 ml erythrocyte lysis buffer consisting of 0.154 mol/l NH4Cl, 5.7 mmol/l K2HPO4 and 0.1 mmol/l EDTA (pH 7.3). Incubation was for 10 min at room temperature. The pre-adipocyte fraction was centrifuged as above, resuspended in 10 ml of DMEM/NUT.MIX.F-12 medium (Gibco, Invitrogen, Sweden) and filtered through a cell strainer with a pore size of 70 µm. After an additional centrifugation step, the fraction was resuspended in DMEM/NUT.MIX.F-12 medium supplemented with 10% fetal calf serum and 100 µg/ml penicillin-streptomycin. Cells were inoculated into 24-well plates at a density of at least 150,000 cells/cm3 (ml) and kept at 37°C in 5% CO2 for not more than 20 h. The cells were then washed and incubated until day 6 in serum-free medium, which consisted of DMEM/NUT.MIX.F-12 medium, 15 mmol/l HEPES, 100 µg/ml penicillin-streptomycin, 2.5 µg/ml amphotericin B (Gibco Invitrogen), 100 nmol/l cortisol, 66 nmol/l insulin, 1 nmol/l triiodothyronine, 33 µmol/l biotin, 17 µmol/l patothenate, 10 µg/ml transferrin (Sigma) and 10 µmol/l rosiglitazone (BRL 49653) (kindly provided by SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK). From day 6 testosterone (Sigma; 1 µmol/l, unless otherwise stated) was added to the culture medium in 12 wells of a 24-well plate. The cells in the remaining wells served as control cells. In some experiments the testosterone receptor blocker flutamide (Sigma; 0.1 µmol/l) was also added. In other experiments the specific testosterone dihydrotestosterone (1 µmol/l) was added instead of testosterone. On day 16 (unless otherwise stated) the experiment was ended and cells and medium analysed as described below. Proteins were extracted from cells in two or three wells using a protein lysis buffer containing 1% Triton X-100, 50 mmol/l Tris-HCl (pH 7.6), 150 mmol/l NaCl and phenylmethylsulfonyl fluoride (1 mmol/l), supplemented with protease inhibitors (Complete; Boehringer Mannheim, Indianapolis, Ind., USA). These total proteins were also used for western blot experiments.
Pre-adipocyte differentiation was assessed by quantifying glycerol-3-phosphate dehydrogenase (GPDH) activity, as described . Cells from two or three wells were washed with PBS (pH 7.4) and harvested in pre-chilled 25 mmol/l Tris-HCl buffer containing 1 mmol/l EDTA (pH 7.4) and 1 mmol/l 2-mercapto-ethanol. After sonication, aliquots of the cell extracts were added to an assay mixture containing 100 mmol/l triethanolamine-HCl buffer (pH 7.5), 2.5 mmol/l EDTA, 0.12 mmol/l NADH, and 0.1 mmol/l 2-mercapto-ethanol. Then GPDH activity was measured spectrophotometrically at 340 nm. The reactions were started by adding 0.2 mmol/l dihydroxyacetone phosphate.
After exposure to testosterone or control medium, cells were subjected to lipolysis experiments as described . In these experiments, cells were washed with DMEM/NUT.MIX.F-12 medium and then incubated in duplicate for 3 h with DMEM/NUT.MIX.F-12 medium containing 20 g/l BSA without or with the following: 10−4 mol/l adrenaline (in the absence or presence of 10−4 mol/l of the α2-adrenoceptor blocker yohimbine); 10−5 mol/l of the non-selective β-adrenoceptor agonist isoprenaline; and 10−3 mol/l of the phosphodiesterase-resistant cyclic AMP analog dibutyryl cyclic AMP (dcAMP). As the tissue available was often not sufficient to get cells to all wells in the 24-well plate, we were unable to use each lipolytic agent in the individual experiments. After incubation the medium was removed and kept at −20°C for subsequent measurement of glycerol concentrations (an index of lipolysis) by bioluminescence . Methodological experiments showed that during this period glycerol release was linear with time. Release of glycerol (µmol/l) was expressed as the concentration in the medium per GPDH activity. GPDH activity was expressed as mU/µg of total protein.
Leptin in medium was measured as described . In brief, 5 ml medium was collected from control and testosterone-treated (1 µmol/l) cells, lyophilised and dissolved in 0.4 ml of distilled water. An aliquot of 100 µl was analysed according to the Quantikine Human Leptin Immunoassay kit protocol (R & D Systems, Abington, UK). Results were corrected for the concentration factor and were expressed as secretion per 24 h in ng/l per GPDH activity.
Western blot experiments
Protein isolation and western blot analysis were done as described . The protein extract from the cell experiments described above were frozen and kept at −70°C until use. Because western blot experiments require at least 100 µg for reliable results with the different antibodies and only small amounts of protein were recovered from individual experiments (usually less than 50 µg from control or testosterone-treated cells), it was necessary to pool proteins from several subjects. The pooling was done as follows: four subjects were randomly picked for one subcutaneous and one omental pool. Protein (30 µg; omental or subcutaneous) was taken from each individual sample into the pool, which had a total of 120 µg of protein. Total protein (100 µg) was loaded on 12% polyacrylamide gels and separated by standard SDS-PAGE. Proteins were transferred on to a PVDF transfer membrane (Hybond-P, Amersham Pharmacia Biotech, Little Chalfont, UK). Blots were blocked for 1 h at room temperature in Tris-buffered saline with 0.1% Tween-20 and 5% non-fat dried milk. This was followed by overnight incubation at 4°C in the presence of primary antibodies directed against β-actin, β1- and β2-adrenergic receptors (AR), hormone-sensitive lipase (HSL) and against several different components of the protein kinase A (PKA) complex i.e. the catalytic subunit of PKA and the regulatory subunits of PKA Iα and IIβ. In addition we used an antibody directed against both the regulatory subunits Iα and IIβ. Primary antibodies against the PKA subunits were from Transduction Laboratories (Lexington, Ky., USA). The antibody against β-actin was from Sigma and those against β1-AR or β2-AR from Santa Cruz Biotechnology (Santa Cruz, Calif., USA). To confirm antibody specificity of the commercial antibodies, positive controls (recombinant protein or tissue extract) were included in all experiments as provided by the manufacturer. An antibody recognising HSL-long and HSL-short was generated in chicken as described . In short, immunised chicken antiserum was affinity-purified against recombinant rat HSL coupled to a CNBr-activate Sepharose 4B column (Amersham Pharmacia Biotech, Uppsala, Sweden). The affinity-purified antibodies were shown to be specific for both forms of HSL. In five of the omental and subcutaneous protein extracts there was enough protein left for a separate western blot experiment to investigate testosterone receptor protein expression using an antibody from Santa Cruz Biotechnology. Secondary antibodies conjugated to horseradish peroxidase were from Sigma (α-mouse 1:5000, α-rabbit 1:2500, and α-chicken 1:2500). Antigen-antibody complexes were detected by chemiluminescences using a kit of reagents from Pierce (Supersignal; Rockford, Ill., USA), and blots were exposed to high-performance chemiluminescence film (Amersham Pharmacia Biotech, Little Chalfont, UK). Films were scanned and the optical density (OD) of each band was analysed using the Image program (National Institute of Health, Bethesda, Md., USA) and expressed as OD mm−2 100 µg−1 of total protein. Methodological studies showed that the OD-reading for a specific protein was proportional to the amount of total protein (50–150 µg) added to the gel.
Values are means ± SEM. All comparisons were made within subjects, i.e. control versus testosterone or subcutaneous versus omental. The western blot experiments were done in pooled extracts. However, the same subjects were included in the control and testosterone-treated sample, so these samples were also statistically considered as pairs. Student’s paired t test was used except when values appeared not to be normally distributed. Then Wilcoxon’s paired signed rank test was used. When three or more samples from the same donor were compared (concentration-response and time-course experiments), ANOVA followed by Student’s paired t test was used. Statistical significance was accepted at a value of less than 0.05. Standard software packages were used for the calculations.
Drugs and chemicals
Adrenaline, BSA fraction V (lot no. A-9418), dcAMP, glycerol kinase from Escherichia coli (G-4509), flutamide, isoprenaline, testosterone and yohimbine were obtained from Sigma. ATP monitoring reagent containing firefly luciferase came from BioThema (Stockholm, Sweden). All chemicals used were of the highest grade of purity that was commercially available.
In the subcutaneous region GPDH activity (mU/µg protein) was 0.17±0.03 in the absence and 0.14±0.03 in the presence of testosterone. Corresponding values for the omental region were 0.13±0.02 and 0.17±0.04. There was no difference in GPDH activity between control and testosterone-treated cells in any region. However, to correct lipolysis for small variations in cell loading and degree of differentiation, glycerol release was related to GPDH activity.
Although the objective of this study was not to directly compare lipolysis rates between pre-adipocytes in the omental and subcutaneous adipose depots, we investigated possible regional variations in lipolytic activity between omental and subcutaneous pre-adipocytes that were differentiated without testosterone. We did this in 14 women, from whom we simultaneously investigated omental and subcutaneous pre-adipocytes that were cultured without testosterone. Basal glycerol release (µmol·l−1·mU GPDH·µg−1 of protein) was similar in the two depots, i.e. 32±6 for the subcutaneous and 36±8 for the omental region. However, adrenaline-induced lipolysis was three times more rapid (p<0.01) in the omental region (482±224) than in the subcutaneous depot (158±48).
Protein amounts in subcutaneous differentiated pre-adipocytes
Specificity of testosterone results
Studies of subgroups
This investigation was predominantly done on women and there was a large variation in BMI. The number of subjects included in the experiments dealt with by Figs. 1 and 2 was large enough for subpopulation analysis, in which 23 women and 3 men were included. Omission of the men from analysis had no important effect on the results. We also checked this material on the basis of BMI, with 13 subjects in one group (BMI 28–40 kg/m2), and 13 subjects in a second group (BMI 41–72 kg/m2). In each of the two subgroups testosterone was seen to affect lipolysis in subcutaneous cells but not in omental cells. A similar division was made on the basis of age for the results shown in Figs. 1 and 2. One subgroup had 13 subjects who were 22 to 36 years old, the other subgroup had 13 subjects who were 42 to 59 years old. The results in these two subgroups were also the same as in the whole group. When all experiments were considered together, we had data on seven men for adrenaline-induced lipolysis in subcutaneous differentiated pre-adipocytes. Basal lipolysis was 31±20 without and 23±15 with 1 µmol/l testosterone (p=0.27). Adrenaline-induced lipolysis was 115±62 without and 56±33 with testosterone (p=0.018).
Our findings on the importance of testosterone for regional differences in the regulation of visceral versus abdominal subcutaneous adipocyte lipolysis have clear implications for the pathophysiology of insulin resistance, bearing in mind the putative roles of sex- and depot-specific effects on fatty acid mobilisation for the development of conditions characterised by insulin resistance [6, 7, 8, 9, 10, 19, 20]. Unfortunately, it is not possible to keep the cells in the culture system after full differentiation, so we were unable to study the testosterone effect after cells had fully matured. On the other hand, it is unlikely that the testosterone effect was related to the differentiation status of the pre-adipocytes, because an effect on lipolysis was seen as early as 3 days after hormone exposure. Our data clearly indicate a depot-specific effect of testosterone on lipolytic regulation. The hormone caused a concentration-dependent and marked decrease (50% at maximum effective concentration) of adrenaline-stimulated lipolysis in differentiated pre-adipocytes from the abdominal subcutaneous but not from the omental fat depot. The effect was observed in moderately obese or morbidly obese subjects and was receptor-specific because it was, in part, reversed by the testosterone receptor blocker flutamide. It was not dependent on the age of the subject. The inhibitory effect of testosterone in subcutaneous cells was as marked in men as in women. Unfortunately, the experiments on omental cells of men were too few (n=3) to allow conclusions about sex-specific effects in this region.
Our results for testosterone and lipolysis are different from those reported in several rodent studies. In rodents, testosterone up-regulates catecholamine-induced lipolysis when investigated in vivo or in vitro using mature fat cells or differentiated pre-adipocytes [21, 22, 23]. This difference between results for humans and for rodents suggests that there are important species differences in the effect of testosterone on lipolysis. Humans given testosterone have increased catecholamine-induced lipolysis in abdominal subcutaneous adipose tissue cultured in vitro . However, this study was not placebo-controlled and it is possible that hormones given at high doses to living subjects have compensatory effects.
We have previously shown that lipolysis induced by noradrenaline is faster in differentiated pre-adipocytes from the omental than in similar pre-adipocytes from the abdominal subcutaneous adipose depot . The same pattern was observed in this study using adrenaline. These findings, taken together with the depot-selective effects of testosterone on pre-adipocytes lipolysis, strongly suggest that the precursor cells for adipocytes in the subcutaneous and visceral region are different. This could be due to the existence of different mesenchymal stem cells in the two adipose areas or to some critical differences in early programming of a common precursor cell as a result of regional variations in the local environment of the relevant adipocytes. Regardless of the mechanisms, these findings could be important for the development of regional variation in lipolysis. In a putative model the relatively high circulating levels of testosterone observed in men and women with PCOS could cause selective inhibition of catecholamine-induced fatty acid mobilisation from the abdominal subcutaneous, but not from visceral adipose tissue. Moreover, a reduced ability of catecholamines to mobilise lipids from the abdominal subcutaneous region could lead to greater fat accumulation in this particular depot in people with upper-body obesity, which is an insulin-resistant condition and more common among men than women, with the exception of PCOS.
Our data do not explain why fat accumulates in the visceral region. It is possible that enhanced lipid synthesis and not lipolytic activity is the major factor behind expansion of visceral adipose tissue. However, our findings could explain why in humans treated with testosterone the volume of visceral adipose tissue and triglyceride accumulation in this adipose region was selectively reduced [25, 26]. A depot-specific inhibitory effect of testosterone on subcutaneous fat cell lipolysis would promote lipid mobilisation from visceral adipose tissue and a more pronounced loss of fat mass in this region.
Although most results were obtained with a high (1 µmol/l) concentration of testosterone, the results are probably still physiologically significant, as the half-maximal effective concentration was 10 nmol/l. This is just above the normal range of circulating testosterone in women (0.5–5.0 nmol/l) and clearly within the normal range in men (10–40 nmol/l).
It has been observed with other incubation protocols that differentiated human pre-adipocytes and mature human cells from both regions express androgen receptors [27, 28]. In theory some of the depot-specific effects of testosterone could be due to our use of a glitazone (i.e. rosiglitazone) during adipocyte differentiation, which could alter expression or signal transduction of testosterone receptors. This, though, is unlikely. Thus, we recently used this differentiation protocol to produce fat cells from human mesenchymal stem cells, which should be more sensitive to rosiglitazone than already committed pre-adipocytes. A similar lipolysis and protein secretory phenotype was observed in human fat cells derived from mesenchymal stem cells and pre-adipocytes . Furthermore, our specificity tests provide strong evidence that the depot differences are not due to absence of testosterone receptors in omental cells or lack of function of these receptors. First, we were able to reproduce the lipolysis results with the very specific agonist dihydrotestosterone. Second, testosterone receptors were present in comparable amounts in both regions. Third, leptin secretion was inhibited by testosterone, confirming earlier data . More importantly, however, we found that both omental and subcutaneous pre-adipocytes are sensitive to testosterone (leptin secretion ≈45% lower after hormone treatment). This suggests that testosterone receptors are functional in both depots, whereas the inhibitory signal to lipolysis is only present in subcutaneous cells. The site-specific effect of testosterone is probably not related to adipocyte differentiation, since the hormone had no effect on pre-adipocyte maturation as measured by GPDH activity, a finding which is consistent with previous results .
Catecholamine-induced lipolysis in human fat cells can be regulated at several levels in the lipolytic cascade . Functional variations in the signalling through α2- or β-adrenergic receptors, as well as alterations in the proteins forming the PKA–HSL complex or in the amount of perilipin, which coats the lipid droplets of adipocytes, could play a role [19, 32, 33, 34]. Although we cannot rule out that testosterone could affect α2-adrenoceptor signalling, the lipolysis data suggest that the important effect of the hormone is inhibition of β-adrenoceptor-mediated lipolysis. As testosterone caused a similar degree of inhibition, regardless of whether lipolysis was stimulated with adrenaline, adrenaline plus yohimbine, isoprenaline or dcAMP, the major inhibitory effect is probably downstream of cyclic AMP formation. No effect of testosterone on protein expression of the different subunits of PKA or on perilipin was observed. However, testosterone caused an almost 50% reduction of the HSL protein in the subcutaneous region but was ineffective in this respect in the omental region. Thus testosterone-induced inhibition of expression of the HSL protein is an important factor in the hormone’s ability to blunt catecholamine-induced lipolysis in subcutaneous adipocytes. Interestingly, previous results with dihydrotestosterone show inhibited protein expression of HSL in isolated mature human subcutaneous fat cells exposed to the hormone for 48 h . At present, we do not know whether the effect of testosterone on HSL is due to transcriptional or translational regulation. The amount of cells available for such detailed studies was far too small.
An additional effect of testosterone in our study was the reduction of β2-adrenoceptor protein. This appeared to be selective, as levels of β1-adrenoceptors were unaltered. Unfortunately, we did not have enough protein for additional studies of other adrenoceptors, G-proteins or phosphodiesterases. However, the lipolysis data suggest that alterations in any additional proteins are of less importance for our findings with testosterone.
Because of lack of tissue, we had to pool adipocyte protein from different donors. It is unlikely that this procedure had an important bearing on findings, because identical amounts of total protein from each subject were pooled together and each control and each testosterone pool was composed of protein from the same donors. Moreover, the amount of specific protein detected by western blot procedures was proportional to the total amount of protein used in the assay and we corrected the protein values for a reference protein (β-actin).
How do the present results relate to sex-specific differences in fat distribution or female sex hormones? At first one would expect men to have very little visceral fat as they have higher testosterone concentrations than women. However, sex-specific factors could still be involved in regional fat distribution, e.g. the more efficient lipid synthesis in visceral fat cells of men than women (not measured in this study), a factor which makes men more prone than women to accumulate visceral adipose tissue. Furthermore, the action of female sex hormones could have counteracting effects when compared with that of testosterone. In rodent fat cells, progesterone has specific lipogenic actions  and the opposite effects to testosterone on thermogenesis regulation, i.e. expression of uncoupling protein 1 in brown adipose tissue . Finally, the situation in living humans could be somewhat different to the in vitro one of an experiment (long-term exposure to high concentrations of rosiglitazone during adipocyte differentiation). For example women, having in general low testosterone concentrations, could be more sensitive than men to an increase of the circulating hormone concentration (such as in PCOS) and thereby be more sensitive than men to the effects of testosterone on subcutaneous adipocyte lipolysis.
In summary, this study shows that testosterone in physiological concentrations inhibits catecholamine-induced lipolysis in differentiated pre-adipocytes from the subcutaneous but not from the visceral fat depot. This could be due to a depot-specific inhibition of the protein expression of HSL by testosterone in subcutaneous adipocytes (and to some extent also to a decrease in the amount of β2-ARs), and could also be an important pathophysiological factor behind the insulin-resistant phenotype both of upper-body obesity (which is common in men), and of hyperandrogenic PCOS.
This study was supported by grants from Åke Wiberg Foundation, Tore Nilsson Foundation, Swedish Medical Society, Foundation for Scientific Work in Diabetes, Swedish Research Council, Swedish Heart and Lung Association, Swedish Diabetes Association, and Novo Nordic Fund. The excellent technical assistance of G. Åström is greatly appreciated. We thank C. Holm of Lund University, Sweden for the HSL antibody.